Search the Newsreel

Prothena 10% owner William P. Scully buys $293,052 of common shares

William P. Scully, a 10% owner of Prothena, recently purchased 34,000 ordinary shares for $293,052, increasing his direct stake to 790,000 shares. Additionally, Manatee Equity Fund LLC, attributed to Scully, acquired 3,500 shares. Scully's spouse also holds 52,000 ordinary shares indirectly.

Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA

Renaissance Technologies LLC increased its stake in Prothena Corporation plc (NASDAQ:PRTA) by 39.5% during the first quarter, now holding 607,515 shares valued at approximately $5.91 million. Institutional investors own 97.08% of the stock, while insiders have recently sold shares but also acquired a significant …

Prothena Corporation PLC (PRTA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Prothena Corporation PLC (PRTA) has an earnings forecast score of 6.67, ranking 318th in the Biotechnology & Medical Research industry. Analysts have an average price target of $18.50 for PRTA, with expectations for the next quarter's revenue at $11.51M and EPS at -$0.24. The …

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

Prothena Corporation PLC (PRTA) Stock News Today

This article provides current stock information for Prothena Corporation PLC (PRTA), including its stock price, market capitalization, and a note that more news will be coming soon. It also lists various sections available on the TradingKey platform for PRTA, such as financials, stock score, …

Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise

Prothena (PRTA) shares saw a modest 2.1% increase despite a significant drop in Q2 2026 collaboration revenue and a return to a net loss. Investors appear to be focused on the company's late-stage pipeline, including two Phase III programs, rather than recent financial results. …

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

Prothena Corporation plc reported its second quarter and first six months 2026 financial results, highlighting a net cash used in operating and investing activities of $25.7 million for the quarter and a net cash provided of $3.2 million for the first six months. The …

Prothena Corporation plc (PRTA) stock price, news, quote and history

This Yahoo Finance page provides a comprehensive overview of Prothena Corporation plc (PRTA) stock, including its current price, historical data, and key financial metrics. It details the company's clinical-stage biotechnology pipeline, focusing on therapies for protein dysregulation diseases, and offers analyst insights and performance …

Prothena publishes corporate overview presentation on protein-dysregulation drug pipeline

Prothena has released a corporate overview detailing its protein-dysregulation drug pipeline, highlighting partnered late-stage programs such as Roche’s prasinezumab for Parkinson’s disease and Novo Nordisk’s coramitug for ATTR cardiomyopathy, both with primary completion expected in 2029. The company also noted a potential $55 million …

Prothena: Q2 Earnings Snapshot

Prothena (NASDAQ: PRTA) turns H1 2026 profit on $50M milestone

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena (PRTA) reported a narrower-than-expected Q2 loss of $0.32 per share, beating the Zacks Consensus Estimate of a $0.39 loss. However, the company missed revenue estimates, posting $1.01 million against an expected $1.94 million, continuing a trend of missing revenue forecasts. Despite the earnings …

Tranche Update on Prothena Corporation plc's Equity Buyback Plan announced on February 27, 2026.

Prothena Corporation plc has provided an update on its equity buyback plan, initially announced on February 27, 2026. Between April 1, 2026, and June 30, 2026, the company repurchased 1,454,898 shares for $14.98 million, representing 2.74% of its shares. This brings the total repurchased …

FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4%

FMR LLC has disclosed a significant 13.8% beneficial ownership stake in Prothena Corporation plc (PRTA), holding 7,199,218 shares as of June 30, 2026. Abigail P. Johnson is noted with sole dispositive power over these shares, and the filing highlights that Fidelity Growth Company Commingled …

Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview

Prothena Corporation PLC is projected to report a loss of 39 cents per share in its upcoming earnings. This information is provided as an earnings preview by Refinitiv. The full article is available through a TradingView subscription.

Technical Reactions to PRTA Trends in Macro Strategies

This article provides a technical analysis of Prothena Corporation Plc (NASDAQ: PRTA) trends, highlighting weak near and mid-term sentiment and a neutral long-term outlook. It outlines three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis …

Prothena General Counsel Michael J. Isaacs disposes of common shares worth $111,080.17

Prothena General Counsel and Company Secretary Michael John Isaacs sold 13,080 ordinary shares in two transactions on July 28-29, totaling $111,080.17. The disposals reduced his beneficial ownership to 35,745 ordinary shares. This information was sourced from an original content publication by Prothena Corporation plc …

Prothena to Report Second Quarter 2026 Financial Results on August 6

Prothena Corporation plc announced it will report its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, after the U.S. financial markets close. The company, a late-stage clinical biotechnology firm, specializes in protein dysregulation with a pipeline targeting …

Prothena Q2 Results: Financial data release set for Aug 6

Prothena Corporation plc is scheduled to release its Q2 and H1 2026 financial results on Thursday, August 6, 2026, after the close of U.S. financial markets. The biotech company, which specializes in protein dysregulation therapies for neurodegenerative diseases, will not hold a conference call …

Form 4 PROTHENA CORP PUBLIC LTD CO For: 30 July By Investing.com

This article reports on the filing of Form 4 for Prothena Corp Public Ltd Co on July 30, as published by Investing.com. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change …

PRTA|Prothena Corporation PLC|Price:8.090|Chg%:-0.320

This article provides a detailed financial overview and market analysis of Prothena Corporation PLC (PRTA). It highlights the company's strong fundamentals, high growth potential, and current valuation as fairly valued within the Biotechnology & Medical Research industry. The report also includes key insights such …

Prothena Corporation PLC (PRTA) Financial Health: Profitability & Balance Sheet Analysis

Prothena Corporation PLC (PRTA) has a robust financial score of 9.21, ranking 10th in the Biotechnology & Medical Research industry. The company demonstrated high operating efficiency with a 1706.36% year-over-year revenue increase and a 154.36% net profit increase in its latest quarter. Its financial …

Prothena Sets Aug. 6 Results Release, No Conference Call

BlackRock (PRTA holder) discloses 6.9% beneficial stake in Prothena common stock

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.9% beneficial ownership stake in Prothena Corporation plc common stock. This translates to 3,587,480 shares, with BlackRock holding sole voting power over 3,533,090 shares and sole dispositive power over all 3,587,480 shares. The filing …

Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Prothena Corporation PLC (PRTA), noting its current valuation score of 6.29 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.05, comparing it to recent highs and lows. The analysis also states …

Prothena Corp. Plc Revenue Breakdown – LSX:A1KAVV

This article provides a revenue breakdown for Prothena Corp. Plc (LSX:A1KAVV). Last year, the company generated 8.25 million EUR, predominantly from its "Collaboration" segment, which contributed 8.20 million EUR. The revenue was primarily sourced from the United States.

Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Prothena Corporation PLC (PRTA), identifying its major shareholders and their respective proportions, along with a breakdown by shareholder types. It also provides institutional shareholding data over several quarters, showing changes in shares held and proportion, and lists …

Rubric Capital Management LP Has $48.60 Million Position in Prothena Corporation plc $PRTA

Prothena Corporation PLC (PRTA) Cash Flow

This article provides a comprehensive overview of Prothena Corporation PLC's (PRTA) cash flow statement, including detailed quarterly and annual data for operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes, offering insight into the company's financial health and stability. The …

PRTA|Prothena Corporation PLC|Price:8.700|Chg%:-0.050

This article provides a detailed financial summary of Prothena Corporation PLC (PRTA), including its latest earnings report, income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS

Top Growth Companies With Insider Ownership For July 2026

This article identifies top growth companies in the United States with significant insider ownership, highlighting that high insider ownership aligns management's interests with shareholders. It provides a list of 10 such companies and then delves deeper into three examples: Kingstone Companies (KINS), Prothena (PRTA), …

Prothena (PRTA) Expected to Announce Quarterly Earnings on Monday